224 related articles for article (PubMed ID: 10501915)
1. Antiangiogenic potential of camptothecin and topotecan.
Clements MK; Jones CB; Cumming M; Daoud SS
Cancer Chemother Pharmacol; 1999; 44(5):411-6. PubMed ID: 10501915
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells.
Jones CB; Clements MK; Wasi S; Daoud SS
Cancer Chemother Pharmacol; 1997; 40(6):475-83. PubMed ID: 9332461
[TBL] [Abstract][Full Text] [Related]
3. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model.
O'Leary JJ; Shapiro RL; Ren CJ; Chuang N; Cohen HW; Potmesil M
Clin Cancer Res; 1999 Jan; 5(1):181-7. PubMed ID: 9918217
[TBL] [Abstract][Full Text] [Related]
5. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
Ruggeri BA; Robinson C; Angeles T; Wilkinson J; Clapper ML
Clin Cancer Res; 2002 Jan; 8(1):267-74. PubMed ID: 11801568
[TBL] [Abstract][Full Text] [Related]
6. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH.
Gabr A; Kuin A; Aalders M; El-Gawly H; Smets LA
Cancer Res; 1997 Nov; 57(21):4811-6. PubMed ID: 9354443
[TBL] [Abstract][Full Text] [Related]
7. Cytoskeletal interference - A new mode of action for the anticancer drugs camptothecin and topotecan.
Wang X; Tanaka M; Krstin S; Peixoto HS; Moura CCM; Wink M
Eur J Pharmacol; 2016 Oct; 789():265-274. PubMed ID: 27474470
[TBL] [Abstract][Full Text] [Related]
8. Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells.
Traganos F; Kapuscinski J; Gong J; Ardelt B; Darzynkiewicz RJ; Darzynkiewicz Z
Cancer Res; 1993 Oct; 53(19):4613-8. PubMed ID: 8402636
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1.
Chen HH; Zhou HJ; Wu GD; Lou XE
Pharmacology; 2004 May; 71(1):1-9. PubMed ID: 15051917
[TBL] [Abstract][Full Text] [Related]
10. Baicalein potently suppresses angiogenesis induced by vascular endothelial growth factor through the p53/Rb signaling pathway leading to G1/S cell cycle arrest.
Ling Y; Chen Y; Chen P; Hui H; Song X; Lu Z; Li C; Lu N; Guo Q
Exp Biol Med (Maywood); 2011 Jul; 236(7):851-8. PubMed ID: 21659383
[TBL] [Abstract][Full Text] [Related]
11. UCN-01 dose-dependent inhibition of normal hyperproliferative cells in mice.
Redkar AA; Meadows GG; Daoud SS
Int J Oncol; 2001 Jul; 19(1):193-9. PubMed ID: 11408942
[TBL] [Abstract][Full Text] [Related]
12. Antimitogenic and proapoptotic activities of methylseleninic acid in vascular endothelial cells and associated effects on PI3K-AKT, ERK, JNK and p38 MAPK signaling.
Wang Z; Jiang C; Ganther H; Lü J
Cancer Res; 2001 Oct; 61(19):7171-8. PubMed ID: 11585751
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrest.
Jones CB; Clements MK; Wasi S; Daoud SS
Cancer Chemother Pharmacol; 2000; 45(3):252-8. PubMed ID: 10663644
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor beta1 induces angiogenesis in vivo with a threshold pattern.
Fajardo LF; Prionas SD; Kwan HH; Kowalski J; Allison AC
Lab Invest; 1996 Mar; 74(3):600-8. PubMed ID: 8600310
[TBL] [Abstract][Full Text] [Related]
15. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
16. Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor.
Morais C; Gobe G; Johnson DW; Healy H
Angiogenesis; 2009; 12(4):365-79. PubMed ID: 19882112
[TBL] [Abstract][Full Text] [Related]
17. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth.
Hotz HG; Reber HA; Hotz B; Sanghavi PC; Yu T; Foitzik T; Buhr HJ; Hines OJ
J Gastrointest Surg; 2001; 5(2):131-8. PubMed ID: 11331474
[TBL] [Abstract][Full Text] [Related]
19. Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion.
Keledjian K; Garrison JB; Kyprianou N
J Cell Biochem; 2005 Feb; 94(2):374-88. PubMed ID: 15526277
[TBL] [Abstract][Full Text] [Related]
20. Glucosaminylmuramyl dipeptide (GMDP) modulates endothelial cell activities in vitro but has no effect on angiogenesis in vivo.
Li CG; Kumar S; Ledger PW; Ponting JM; Carette M; Allan E
Inflamm Res; 1997 Sep; 46(9):348-53. PubMed ID: 9339390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
